CEL-SCI (CVM) Enrolls 20 Patients In August In Its Phase 3 Immunotherapy Head And Neck Cancer Trial
9/3/2014 9:09:02 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.
“Given that summer months generally have a slower rate of enrollment for clinical trials, our goal was to maintain the enrollment level compared to the three months prior to the summer. In fact, we did better. We continue to add more centers and countries to the study. As we head into the fall, we believe the pace of patient enrollment will further increase,” stated CEL-SCI Chief Executive Officer Geert Kersten.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by